Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

Completed · Phase 2

Conditions studied: COVID, Sars-CoV2, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress

In brief

The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease

Key facts

Study ID

NCT04419025

Run by

Cambridge Health Alliance

People needed

165

Starts

2020-09-23

Expected to finish

2021-05-14

Last updated by the study team

2021-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• known or suspect COVID-19 disease AND one or more of the following influenza-like symptoms, including: diarrhea vomiting fever (subjective or measured) chills myalgias fatigue sore throat headache cough nasal/sinus congestion or rhinorrhea shortness of breath chest pain

You may not qualify if…

• Minors, pregnant women and people unable to provide informed consent are excluded from this study

Where it is running

• CHA Cambridge Hospital — Cambridge, Massachusetts, United States
• CHA Everett Hospital — Everett, Massachusetts, United States
• CHA Respiratory Clinic — Somerville, Massachusetts, United States
• CHA Somerville campus — Somerville, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.